Management of the patient with drug-induced liver disease

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Drug-induced liver disease is a common clinical problem. Although adverse reactions appear rare, occurring in 1:10,000 to 1:100,000 individuals exposed to a given drug (1), incidence figures in a study from France for all types of hepatic drug reactions were 13.9G2.4 per 100,000, with 12% being hospitalized and 6% dying from the adverse reaction. The author believes that this is an underestimate of the true incidence of drug-induced liver disease (2). Similarly, in a report from the United States, the medical records of an HMO were examined for elevated liver tests. They found an incidence of 40.6 cases per 100,000 for drug-associated liver test abnormalities when compared with an incidence of 15.4 per 100,000 for alcohol as a cause of the elevated liver tests (3). Adverse hepatic drug reactions are common in the outpatient setting as well. In one report, 84% of adverse hepatic drug reactions occurred in outpatients (2). Identification of hepatotoxic drug reactions in the outpatient setting is difficult as multiple healthcare providers may prescribe medications for a given patient and if the reaction is delayed, as with clavulanic acid-containing drugs, cause and effect may be difficult to establish. In addition, the spontaneous reporting of adverse drug reactions is more likely to occur with hospital-based physicians than with nonhospital-based physicians, leading to an underestimate of the frequency of drug-induced hepatotoxicity in outpatients (4). Thus, the clinician is likely to see a number of patients with drug-induced liver injury during the course of their practice and the management of these patients will be a common issue. This chapter will focus on how to manage the patient with drug-induced liver injury. A brief discussion of how the diagnosis is established is followed by a discussion of whether or not discontinuation of the offending medication is required and whether a rechallenge or use of a medication of the same class is safe. Treatment of complications of the adverse reactions will also be discussed and, lastly, the criteria for referral to a liver transplant center will be reviewed. Although the author will attempt to use data from studies to support most of the recommendations provided in this chapter, on occasion the recommendations will be based on the author’s experience in managing these types of patients.

Original languageEnglish (US)
Title of host publicationDrug-Induced Liver Disease, Second Edition
PublisherCRC Press
Pages345-352
Number of pages8
ISBN (Electronic)9781420021141
ISBN (Print)9780849398964
StatePublished - Jan 1 2007

Fingerprint

Chemical and Drug Induced Liver Injury
Liver
Outpatients
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Incidence
Physicians
Clavulanic Acid
Health Maintenance Organizations
Practice Management
Health Personnel
France
Medical Records
Referral and Consultation
Alcohols
Transplants

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Boyer, T. D. (2007). Management of the patient with drug-induced liver disease. In Drug-Induced Liver Disease, Second Edition (pp. 345-352). CRC Press.

Management of the patient with drug-induced liver disease. / Boyer, Thomas D.

Drug-Induced Liver Disease, Second Edition. CRC Press, 2007. p. 345-352.

Research output: Chapter in Book/Report/Conference proceedingChapter

Boyer, TD 2007, Management of the patient with drug-induced liver disease. in Drug-Induced Liver Disease, Second Edition. CRC Press, pp. 345-352.
Boyer TD. Management of the patient with drug-induced liver disease. In Drug-Induced Liver Disease, Second Edition. CRC Press. 2007. p. 345-352
Boyer, Thomas D. / Management of the patient with drug-induced liver disease. Drug-Induced Liver Disease, Second Edition. CRC Press, 2007. pp. 345-352
@inbook{cdfccd6f5d4642a7aedef1e5825cbe63,
title = "Management of the patient with drug-induced liver disease",
abstract = "Drug-induced liver disease is a common clinical problem. Although adverse reactions appear rare, occurring in 1:10,000 to 1:100,000 individuals exposed to a given drug (1), incidence figures in a study from France for all types of hepatic drug reactions were 13.9G2.4 per 100,000, with 12{\%} being hospitalized and 6{\%} dying from the adverse reaction. The author believes that this is an underestimate of the true incidence of drug-induced liver disease (2). Similarly, in a report from the United States, the medical records of an HMO were examined for elevated liver tests. They found an incidence of 40.6 cases per 100,000 for drug-associated liver test abnormalities when compared with an incidence of 15.4 per 100,000 for alcohol as a cause of the elevated liver tests (3). Adverse hepatic drug reactions are common in the outpatient setting as well. In one report, 84{\%} of adverse hepatic drug reactions occurred in outpatients (2). Identification of hepatotoxic drug reactions in the outpatient setting is difficult as multiple healthcare providers may prescribe medications for a given patient and if the reaction is delayed, as with clavulanic acid-containing drugs, cause and effect may be difficult to establish. In addition, the spontaneous reporting of adverse drug reactions is more likely to occur with hospital-based physicians than with nonhospital-based physicians, leading to an underestimate of the frequency of drug-induced hepatotoxicity in outpatients (4). Thus, the clinician is likely to see a number of patients with drug-induced liver injury during the course of their practice and the management of these patients will be a common issue. This chapter will focus on how to manage the patient with drug-induced liver injury. A brief discussion of how the diagnosis is established is followed by a discussion of whether or not discontinuation of the offending medication is required and whether a rechallenge or use of a medication of the same class is safe. Treatment of complications of the adverse reactions will also be discussed and, lastly, the criteria for referral to a liver transplant center will be reviewed. Although the author will attempt to use data from studies to support most of the recommendations provided in this chapter, on occasion the recommendations will be based on the author’s experience in managing these types of patients.",
author = "Boyer, {Thomas D}",
year = "2007",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780849398964",
pages = "345--352",
booktitle = "Drug-Induced Liver Disease, Second Edition",
publisher = "CRC Press",

}

TY - CHAP

T1 - Management of the patient with drug-induced liver disease

AU - Boyer, Thomas D

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Drug-induced liver disease is a common clinical problem. Although adverse reactions appear rare, occurring in 1:10,000 to 1:100,000 individuals exposed to a given drug (1), incidence figures in a study from France for all types of hepatic drug reactions were 13.9G2.4 per 100,000, with 12% being hospitalized and 6% dying from the adverse reaction. The author believes that this is an underestimate of the true incidence of drug-induced liver disease (2). Similarly, in a report from the United States, the medical records of an HMO were examined for elevated liver tests. They found an incidence of 40.6 cases per 100,000 for drug-associated liver test abnormalities when compared with an incidence of 15.4 per 100,000 for alcohol as a cause of the elevated liver tests (3). Adverse hepatic drug reactions are common in the outpatient setting as well. In one report, 84% of adverse hepatic drug reactions occurred in outpatients (2). Identification of hepatotoxic drug reactions in the outpatient setting is difficult as multiple healthcare providers may prescribe medications for a given patient and if the reaction is delayed, as with clavulanic acid-containing drugs, cause and effect may be difficult to establish. In addition, the spontaneous reporting of adverse drug reactions is more likely to occur with hospital-based physicians than with nonhospital-based physicians, leading to an underestimate of the frequency of drug-induced hepatotoxicity in outpatients (4). Thus, the clinician is likely to see a number of patients with drug-induced liver injury during the course of their practice and the management of these patients will be a common issue. This chapter will focus on how to manage the patient with drug-induced liver injury. A brief discussion of how the diagnosis is established is followed by a discussion of whether or not discontinuation of the offending medication is required and whether a rechallenge or use of a medication of the same class is safe. Treatment of complications of the adverse reactions will also be discussed and, lastly, the criteria for referral to a liver transplant center will be reviewed. Although the author will attempt to use data from studies to support most of the recommendations provided in this chapter, on occasion the recommendations will be based on the author’s experience in managing these types of patients.

AB - Drug-induced liver disease is a common clinical problem. Although adverse reactions appear rare, occurring in 1:10,000 to 1:100,000 individuals exposed to a given drug (1), incidence figures in a study from France for all types of hepatic drug reactions were 13.9G2.4 per 100,000, with 12% being hospitalized and 6% dying from the adverse reaction. The author believes that this is an underestimate of the true incidence of drug-induced liver disease (2). Similarly, in a report from the United States, the medical records of an HMO were examined for elevated liver tests. They found an incidence of 40.6 cases per 100,000 for drug-associated liver test abnormalities when compared with an incidence of 15.4 per 100,000 for alcohol as a cause of the elevated liver tests (3). Adverse hepatic drug reactions are common in the outpatient setting as well. In one report, 84% of adverse hepatic drug reactions occurred in outpatients (2). Identification of hepatotoxic drug reactions in the outpatient setting is difficult as multiple healthcare providers may prescribe medications for a given patient and if the reaction is delayed, as with clavulanic acid-containing drugs, cause and effect may be difficult to establish. In addition, the spontaneous reporting of adverse drug reactions is more likely to occur with hospital-based physicians than with nonhospital-based physicians, leading to an underestimate of the frequency of drug-induced hepatotoxicity in outpatients (4). Thus, the clinician is likely to see a number of patients with drug-induced liver injury during the course of their practice and the management of these patients will be a common issue. This chapter will focus on how to manage the patient with drug-induced liver injury. A brief discussion of how the diagnosis is established is followed by a discussion of whether or not discontinuation of the offending medication is required and whether a rechallenge or use of a medication of the same class is safe. Treatment of complications of the adverse reactions will also be discussed and, lastly, the criteria for referral to a liver transplant center will be reviewed. Although the author will attempt to use data from studies to support most of the recommendations provided in this chapter, on occasion the recommendations will be based on the author’s experience in managing these types of patients.

UR - http://www.scopus.com/inward/record.url?scp=77955333636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955333636&partnerID=8YFLogxK

M3 - Chapter

SN - 9780849398964

SP - 345

EP - 352

BT - Drug-Induced Liver Disease, Second Edition

PB - CRC Press

ER -